Current and Future Treatment Strategies for Acute Myeloid Leukemia

Gain insight on the latest investigative treatments for AML, including targeted therapies for FLT3- and IDH1/2-positive AML and combination strategies.
Naval G. Daver, MD


Gain insight on the latest investigative treatments for patients with FLT3-positive AML with this expert commentary.

Naval G. Daver, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits Released: July 31, 2020 Expired: July 30, 2021


Listen to Naval G. Daver, MD, discuss his thoughts on the most promising investigational agents and treatment strategies currently in clinical trials for the treatment of patients with acute myeloid leukemia (AML).

Naval G. Daver, MD Released: August 14, 2020
Provided by Clinical Care Options, LLC.

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley

Supported by an educational grant from
Daiichi Sankyo, Inc.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.


More info

CCO’s educational programs are available completely free of charge on the,, and Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?